logo BDSP

Base documentaire

  1. Zidovudine response relationships in early human immunodeficiency virus infection.

    Article - En anglais


    To examine predictors of magnitude of CD4+ response to treatment of human immunodeficiency virus (HIV) infection with zidovudine.


    This was a post hoc analysis of randomized placebo-controlled clinical trial in a multicenter trial, 1423 asymptomatic HIV-positive subjects with CD4+ cell counts less than 500 mm-3 were given 500 mg/day zidovudine, 1500 mg/day zidovudine, or placebo.

    The main outcome measure was change in The CD4+ cell counts over time.


    This study suggests that earlier treatment with zidovudine results in a larger increment in the CD4+ cell count.

    Mots-clés Pascal : Zidovudine, Chimiothérapie, Traitement, SIDA, Virose, Infection, Séropositivité, Asymptomatique, Etude multicentrique, Randomisation, Homme, Epidémiologie, Pharmacocinétique, Placebo, Immunopathologie, Hémopathie, Cellule CD4+

    Mots-clés Pascal anglais : Chemotherapy, Treatment, AIDS, Viral disease, Infection, Seropositivity, Asymptomatic, Multicenter study, Randomization, Human, Epidemiology, Pharmacokinetics, Placebo, Immunopathology, Hemopathy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0127360

    Code Inist : 002B02S05. Création : 199406.